Neoadjuvant FOLFIRINOX or Nab-paclitaxel With Gemcitabine for Borderline Resectable Pancreatic Cancer

• Status: Active, not recruiting
• Trial end date: 2023-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study is to clarify the efficacy and safety of neoadjuvant FOLFIRINOX and nab-paclitaxel + gemcitabine for borderline resectable pancreatic cancer.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Nagoya University
• Treatments: Albumin-Bound Paclitaxel; Folfirinox; Gemcitabine; Paclitaxel

Criteria

Inclusion Criteria:

1. Borderline resectable pancreatic cancer (based on NCCN guideline version 2.2015)

2. first treatment for pancreatic cancer

3. performance status 0 or 1

4. adequate one marrow function

5. adequate renal function

6. obtained informed consent

Exclusion Criteria:

1. other active concomitant malignancies

2. other severe medical conditions; contraindication of FOLFIRINOX, paclitaxel and gemcitabine

3. pregnant women

4. no informed consent